Ashland Inc Dossier
|
SectorMaterials IndustrySpecialty Chemicals Beta (adjusted)0.60 Intrinsic Value $74.77median of 5 methods · middle span $65-$75based on filings through 30 Jun 2026 Market Price $67.92Price as of 30 Sep 2026 Near fair valueIntrinsic value is 10% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $3.1B Enterprise Value $4B Shares Outstanding 49.5M diluted Moat Rating None Next Earnings Date4 Nov 2026 Last ex-dividend1 Sep 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ashland Inc. is a high-margin specialty ingredients and additives company with strong market positions in consumer-focused end markets like pharmaceuticals and personal care. While near-term operational headwinds at its Hopewell facility and softer industrial demand have pressured recent earnings, the company's underlying commercial performance remains resilient. The recent activist campaign launched by Ancora Alternatives LLC in June 2026 serves as a major catalyst, urging the board to pursue a full sale of the company. Ancora's sum-of-the-parts and take-out analysis suggests a potential valuation of $76 to $81 per share, representing a significant premium over current trading levels and providing a strong margin of safety for investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$70.00 Mean target$80.18 High · most bullish analyst$90.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The board rejects activist demands and attempts to remain standalone, leading to a prolonged proxy fight. Operational challenges at Hopewell persist, and continued weakness in industrial and energy-related end markets limits near-term EBITDA recovery. Base CaseCentral scenario The board engages constructively with Ancora Alternatives and other interested parties (such as Standard Industries) to evaluate strategic alternatives. A competitive sale process is initiated, unlocking the intrinsic value of Ashland's high-margin, strategically scarce specialty chemical assets. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |